StockData
Korsana Biosciences, Inc. logo

Korsana Biosciences, Inc. (KRSA) stock

KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30498% above fair value
$32.50−0.18 (-0.55%)

Close on Nov 17, 2026Market cap $152.14MP/E –Yield –

Korsana Biosciences ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Korsana Biosciences's ebitda for the twelve months ending Dec 31, 2023 was -$12.95M. For fiscal 2023 it was -$12.95M. The highest annual figure on record is -$12.95M in fiscal 2023.

Annual ebitda

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$12.95M–
FY2022Dec 31, 2022-$18.48M–
FY2021Dec 31, 2021-$54.72M–
FY2020Dec 31, 2020-$78.97M–
FY2019Dec 31, 2019-$122.34M–
FY2018Dec 31, 2018-$113.72M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$1.80M–
Q3 FY2023Sep 30, 2023-$6.02M–
Q2 FY2023Jun 30, 2023-$1.87M–
Q1 FY2023Mar 31, 2023-$3.28M–
Q4 FY2022Dec 31, 2022-$4.46M–
Q3 FY2022Sep 30, 2022-$4.52M–
Q2 FY2022Jun 30, 2022-$13.42M–
Q1 FY2022Mar 31, 2022-$12.94M–
Q4 FY2021Dec 31, 2021-$14.29M–
Q3 FY2021Sep 30, 2021-$10.69M–
Q2 FY2021Jun 30, 2021-$16.08M–
Q1 FY2021Mar 31, 2021-$13.14M–
Q4 FY2020Dec 31, 2020-$18.75M–
Q3 FY2020Sep 30, 2020-$21.18M–
Q2 FY2020Jun 30, 2020-$19.07M–
Q1 FY2020Mar 31, 2020-$19.96M–
Q4 FY2019Dec 31, 2019-$25.93M–
Q3 FY2019Sep 30, 2019-$27.32M–
Q2 FY2019Jun 30, 2019-$32.25M–
Q1 FY2019Mar 31, 2019-$36.86M–
Q4 FY2018Dec 31, 2018-$30.44M–
Q3 FY2018Sep 30, 2018-$28.89M–
Q2 FY2018Jun 30, 2018-$29.38M–
Q1 FY2018Mar 31, 2018-$24.93M–

More Korsana Biosciences figures

See a number that looks wrong?